-
Mashup Score: 2
For hematologic malignancy (HM) patients admitted to the ICU, survival is 49 percent at seven days and 21 percent at 12 months.
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Rare Disease Impact on Understanding Common Diseases - 11 day(s) ago
Cat Lutz, PhD, MBA, VP at JAX Rare Disease Translational Center, discusses rare disease research’s impact on understanding common diseases.
Source: CheckRare.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 2
For hematologic malignancy (HM) patients admitted to the ICU, survival is 49 percent at seven days and 21 percent at 12 months.
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Loader - 25 day(s) ago
We have noticed an unusual activity from your IP 199.16.157.181 and blocked access to this
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Rare Disease Impact on Understanding Common Diseases - 25 day(s) ago
Cat Lutz, PhD, MBA, VP at JAX Rare Disease Translational Center, discusses rare disease research’s impact on understanding common diseases.
Source: CheckRare.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 0
For patients with polycythemia vera, rusfertide treatment reduces the use of phlebotomy and maintains hematocrit of less than 45 percent.
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
The U.S. FDA has approved Breyanzi as the first CD19-directed CAR T-cell therapy for adult patients with relapsed or refractory CLL or SLL.
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Loader - 1 month(s) ago
We have noticed an unusual activity from your IP 199.16.157.181 and blocked access to this
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Rusfertide Treatment Beneficial for Patients With Polycythemia Vera - 1 month(s) ago
For patients with polycythemia vera, rusfertide treatment reduces the use of phlebotomy and maintains hematocrit of less than 45 percent.
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The Importance of Rare Disease Registries - 1 month(s) ago
Alaa Hamed, MD, Global Head of Medical Affairs Rare Diseases at Sanofi, discusses the importance of rare disease registries.
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
For hematologic malignancy patients admitted to the intensive care unit, survival is 49 percent at seven days and 21 percent at 12 months #CheckRare #RareDisease https://t.co/LUP45KZQpu